Literature DB >> 21319507

Comparison of histopathologic classification and surgical stage by cytokeratin 8 and cytokeratin 18 in endometrial cancer.

S Kabukcuoglu1, S S Ozalp, O T Yalcin, E Colak, A A Abubakar.   

Abstract

PURPOSE OF INVESTIGATION: The aim of the study was to show the role of the cytoskeletal proteins CK8 and CK18 in endometrial cancer invasion and to histopathologically classify endometrial cancer patients.
METHODS: This study was a prospective analysis of 49 histologic samples of consecutively surgically operated endometrial cancer patients. After histopathologic classification the most invasive tumor area was selected for immunohistochemistry. Monoclonal antihuman keratin Ab-4 and keratin Ab-1 were applied.
RESULTS: CK8 and CK18 stained tumoral tissue and tumoral cell debris in the lymphovascular space were significantly correlated with stage (p < or = 0.005).
CONCLUSIONS: To understand the causes of early treatment failure in endometrial cancer patients, further studies are needed to show the role of enhancing factors of endometrial cancer invasion.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21319507

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  3 in total

1.  Low-dose Cd induces hepatic gene hypermethylation, along with the persistent reduction of cell death and increase of cell proliferation in rats and mice.

Authors:  Bo Wang; Yang Li; Yi Tan; Xiao Miao; Xu-Dong Liu; Chen Shao; Xiao-Hui Yang; Subat Turdi; Li-Jie Ma; Jun Ren; Lu Cai
Journal:  PLoS One       Date:  2012-03-23       Impact factor: 3.240

Review 2.  Cytokeratin Expression Pattern in Human Endometrial Carcinomas and Lymph Nodes Micrometastasis: a Mini-review.

Authors:  Danuta Vasilevska; Vilius Rudaitis; Aneta Adamiak-Godlewska; Anna Semczuk-Sikora; Dorota Lewkowicz; Dominika Vasilevska; Andrzej Semczuk
Journal:  J Cancer       Date:  2022-03-14       Impact factor: 4.207

3.  Three are better than one: plasminogen receptors as cancer theranostic targets.

Authors:  Patrizia Ceruti; Moitza Principe; Michela Capello; Paola Cappello; Francesco Novelli
Journal:  Exp Hematol Oncol       Date:  2013-04-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.